CAMPBELL, Calif., December 2, 2024 – Saama, a provider of AI-based solutions that accelerate clinical development and commercialization, was again named as a Leader in the “Life Sciences Clinical Data and Analytics (D&A) Platforms PEAK Matrix® Assessment 2024” by Everest Group. This year’s annual report evaluated 18 clinical D&A platform providers on market impact as well as vision and capability. For the second consecutive year, Saama is positioned in the prominent Leaders quadrant for its overall recognition across these categories.
“We are deeply honored to once again be recognized as a Leader by Everest Group,” said Prasanna Rao, Chief Products & Innovation Officer, Saama. “This milestone reflects the unparalleled capabilities of the Saama platform in harnessing complex clinical data to drive actionable insights. By accelerating clinical trials with efficiency and precision, we continue to empower our life sciences partners to deliver transformative therapies to patients worldwide, faster than ever before.”
Saama’s solutions leverage the industry’s most advanced technology and AI capabilities to empower study teams to efficiently manage the growing volume and complexity of today’s clinical trial data. Throughout studies, data are centralized and standardized from diverse sources to enable streamlined medical review processes, improve patient safety oversight, predict participant behavior, accelerate clinical signal discovery, and more. With Saama as a strategic partner, clinical trial sponsors and CROs have an AI-driven clinical data and analytics platform that improves productivity, speeds data analysis, and provides deeper insights into patient behaviors and outcomes.
Everest Group’s PEAK Matrix® is a proprietary framework used for evaluating service and technology providers. The dimensions of the matrix include measuring impact created in the market and assessment of vision and capability based on the ability to deliver products successfully.
Among Saama’s strengths outlined in the report include:
- Continuously being at the forefront of AI and GenAI application in the clinical D&A value chain
- Responsiveness of support services, as well as proactiveness
- Competitively priced and flexible pricing models
“The Saama platform is built on more than a decade of AI research and models specific to the life sciences which provides our customers with the state-of-the-art in technology to fuel their research,” said Malaikannan Sankarasubbu, Chief Technology & AI Officer, Saama. “This foundation coupled with our team’s ability to fine tune our large language models to adapt to study-specific needs allows us to continuously deliver value and insights in real time to clinical research teams.”
This year’s PEAK Matrix Assessment of Saama is available for download here.
The Saama platform of AI-enabled SaaS solutions supports the full spectrum of clinical development. To learn more about the Saama platform and its custom solutions and services or to schedule a personalized demonstration, visit saama.com.
About Saama
Saama develops life science solutions that accelerate the delivery of therapies to patients. With innovative AI technologies, Saama drives breakthrough intelligence into clinical and commercial operations. The Saama platform powered the clinical trial that led to the world’s first COVID-19 vaccine. Headquartered in Campbell, CA, with employees around the globe, Saama is committed to helping customers save and improve lives. Discover more at saama.com.
Contacts:
Kate Mikus
Head of Global Marketing
Heather Shea
Catalytic Agency on behalf of Saama
[email protected]
